Abbott Laboratories is rebounding from last year’s manufacturing shutdown of its U.S. baby formula plant thanks to strong medical device sales taking the place of lost revenue of COVID-19 tests.
Subscribe to:
Post Comments (Atom)
< + > A Healthcare IT Leader Preview of ViVE 2026
As those who read Healthcare IT Today regularly know, we attend a lot of healthcare IT conferences throughout the year. One of the newest ...
No comments:
Post a Comment